Number of significant genes and fold change. by Gordon A. Barr (11163243)

Application of Machine Learning-Based Models to Understand and Predict Critical Flux of Oil-in-Water Emulsion in Crossflow Microfiltration by Henry J. Tanudjaja (12106715)

Subjects:

Base-case results. by Parima Hirunwiwatkul (14797370)

NN analysis to assign the importance of variables. by Sulmaz Ghahramani (3387635)

Base-case results. by Unchalee Permsuwan (5478434)

Averages of the fold decreases in the MICs of tested antibiotics in the presence of the tested compounds. by Safaa Abdel-Aal Mohamed Abdel-Karim (13175696)

Base case regression results. by Florian Hofer (7377338)

Subjects:

Base case results. by Andrea Alcaraz (6573002)

Base-case analysis. by Yiping An (20609789)

“…At a CET of 0.51 times GDP per capita (US$6,394.536), the base-case analysis showed that the incremental costs of AOM relative to PP1M after 10 years of treatment were US$1,926.373 with an incremental gain of 0.306 QALYs. …”

Base-case model inputs. by Rajabali Daroudi (2824832)

Input parameters for the base-case analysis. by R. J. S. D. Heine (17889199)

Subjects:

The results of the base case model. by Lei Hua (465535)

Base-case results. by Ping Chen (89712)

The base case analysis. by Wenwang Lang (20293527)

“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”

Base-case results. by Shuo Kang (1306860)

“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”

Base-case results. by Mingxi Xie (19812594)

“…The model time-frame was one-year. Base-case analysis and sensitivity analysis were performed. …”

Base-case analysis. by Akiko Kowada (14659965)

“…The willingness-to-pay (WTP) threshold was set at US$50,000 per QALY gained. In the base-case analysis, HTLV-1 antenatal screening (US$76.85, 24.94766 QALYs, 24.94813 LYs, ICER; US$40,100 per QALY gained) was cost-effective compared with no screening (US$2.18, 24.94580 QALYs, 24.94807 LYs). …”

The percentage of significant partial correlations (with sign matching interaction in either direction), as recovered from the base case model. by Susanne Pinto (13767952)

Deterministic result of the base-case analysis. by Sudewi Mukaromah Khoirunnisa (15288505)

“…Efficacy data and baseline characteristics in the base-case analysis were primarily derived from the 11-year results of the HERA trial. …”

Base-case estimated number of patients categorised in different phenotypes and age groups and their base-case cost of management. by Siew Chin Ong (9314213)